A First-in-Human, Multi-centre, Open-label, Phase 1 Clinical Study With RNA Oligonucleotide Drug MTL-CEBPA to Investigate Its Safety and Tolerability in Patients With Advanced Liver Cancer
Phase of Trial: Phase I
Latest Information Update: 21 Jun 2017
At a glance
- Drugs MTL CEBPA (Primary)
- Indications Liver cancer
- Focus Adverse reactions; First in man
- Acronyms OUTREACH
- Sponsors MiNA Therapeutics
- 13 Jun 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 13 Jun 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
- 06 Jun 2017 According to trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology, no DLTs were reported to date.